Article
Celgene's Revlimid Receives Expanded Approval in Europe Following Similar FDA Approval
After the FDA approved lenalidomide for use in chemotherapy-naive multiple myeloma (MM) patients, the European Commission has followed suit. Revlimid was approved today by EC in MM patients, previously untreated and transplant-ineligible.
Regulators in Europe have followed the example of their counterparts across the Atlantic and expanded approval on Celgene’s big-selling multiple myeloma drug Revlimid to include newly-diagnosed patients.
The European Commission has approved Revlimid (lenalidomide) for adults with previously untreated MM who are not eligible for transplant. It is currently marketed in combination with dexamethasone for patients who have received at least one prior therapy.
Read the complete article at PharmaTimes: http://bit.ly/1zTEsDi
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
